Kura Oncology, Inc. (KURA) stock
KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)
Close on Nov 18, 2026Market cap $652.97MP/E –Yield –
Kura Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Kura Oncology's operating margin for the twelve months ending Sep 30, 2026 was -394.3%. For fiscal 2025 it was -449.9%, against -358.5% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -449.9% | −91.4 |
| FY2024 | Dec 31, 2024 | -358.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -326.9% | +58.6 |
| Q2 FY2026 | Jun 30, 2026 | -349.8% | +125.5 |
| Q1 FY2026 | Mar 31, 2026 | -431.5% | +27.1 |
| Q4 FY2025 | Dec 31, 2025 | -497.6% | – |
| Q3 FY2025 | Sep 30, 2025 | -385.5% | – |
| Q2 FY2025 | Jun 30, 2025 | -475.3% | – |
| Q1 FY2025 | Mar 31, 2025 | -458.6% | – |
See a number that looks wrong?